Safety and Efficacy of Oral Azacitidine (CC-486) Administered in Extended Treatment Schedules to Patients with Lower-Risk Myelodysplastic Syndromes

被引：0
|
作者：
Garcia-Manero, Guillermo [1 ]
Gore, Steven D. [2 ]
Kambhampati, Suman [3 ]
Scott, Bart L. [4 ]
Tefferi, Ayalew [5 ]
Cogle, Christopher R. [6 ]
Edenfield, William [7 ]
Hetzer, Joel [8 ]
Kumar, Keshava [8 ]
Skikne, Barry S. [9 ]
机构：
[1] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
[2] Johns Hopkins Univ, Sidney Kimmel Canc Ctr, Baltimore, MD USA
[3] Univ Kansas Med Ctr, Dept Hematol Oncol, Kansas City, KS USA
[4] Fred Hutchinson Canc Res Ctr, Div Clin Res, Seattle, WA 98104 USA
[5] Mayo Clin, Dept Internal Med, Div Hematol, Rochester, MN USA
[6] Univ Florida, Gainesville, FL 32611 USA
[7] Canc Ctr Carolinas, Greenville, SC USA
[8] Celgene Corp, Summit, NJ USA
[9] Celgene Corp, Overland Pk, KS USA
来源：
BLOOD | 2012年 / 120卷 / 21期
关键词：
D O I：
10.1182/blood.V120.21.424.424
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
424
引用
收藏
页数：3
相关论文
共 50 条
  • [41] CC-486 (Oral Azacitidine) Maintenance Therapy Is Well Tolerated after Allogeneic Hematopoietic Stem Cell Transplantation (AlloHSCT) in Patients with Myelodysplastic Syndromes (MDS) or Acute Myeloid Leukemia (AML)
    de Lima, Marcos
    Oran, Betul
    Papadopoulos, Esperanza B.
    Scott, Bart L.
    William, Basem M.
    Giralt, Sergio A.
    Champlin, Richard E.
    Hetzer, Joel
    Tosolini, Alessandra
    Laille, Eric
    Skikne, Barry S.
    Craddock, Charles
    BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2016, 22 (03) : S312 - S313
  • [42] Prognostic significance of hyperfibrinogenemia in patients with lower-risk myelodysplastic syndromes
    Shinji Ogura
    Shoichiro Yonei
    Tomohiko Tanigawa
    Masahiro Akimoto
    Aki Sakurai
    Yuriko Fujita
    Chisako Ito
    Yoshinobu Aisa
    Tomonori Nakazato
    Annals of Hematology, 2020, 99 : 189 - 191
  • [43] Azacitidine in Lower-Risk Myelodysplastic Syndromes: AMeta-Analysis of Data from Prospective Studies
    Komrokji, Rami
    Swern, Arlene S.
    Grinblatt, David
    Lyons, Roger M.
    Tobiasson, Magnus
    Silverman, Lewis R.
    Sayar, Hamid
    Vij, Ravi
    Fliss, Albert
    Tu, Nora
    Sugrue, Mary M.
    ONCOLOGIST, 2018, 23 (02): : 159 - 170
  • [44] Treatment with Oral Azacitidine in Elderly Patients with Higher Risk Myelodysplastic Syndromes after Response to Subcutaneous Azacitidine
    Santini, Valeria
    Amato, Cristina
    Caciagli, Barbara
    Consagra, Angela
    Rigodanza, Luca
    de Pourcq, Sven
    Cassari, Margherita
    Tofacchi, Elena
    Mattiuz, Giorgio
    Raddi, Marco Gabriele Gabriele
    Sanna, Alessandro
    BLOOD, 2022, 140 : 12313 - 12314
  • [45] Efficacy and Safety of Venetoclax in Combination with Azacitidine for the Treatment of Patients with Treatment-Naive, Higher-Risk Myelodysplastic Syndromes
    Garcia, Jacqueline S.
    Platzbecker, Uwe
    Odenike, Olatoyosi
    Fleming, Shaun
    Fong, Chun Yew
    Cook, Rachel
    Jacoby, Meagan
    Nowak, Daniel
    Chyla, Brenda
    Zhou, Ying
    Ku, Grace
    Potluri, Jalaja
    Garcia-Manero, Guillermo
    BLOOD, 2023, 142
  • [46] A phase II study of oral azacitidine (CC-486) in combination with pembrolizumab (PEMBRO) in patients with metastatic melanoma (MM).
    Keung, Emily
    Burton, Elizabeth M.
    Amaria, Rodabe Navroze
    Glitza, Isabella Claudia
    Patel, Sapna Pradyuman
    Diab, Adi
    Yee, Cassian
    Wong, Michael K.
    Hwu, Wen-Jen
    Hwu, Patrick
    Woodman, Scott Eric
    Tetzlaff, Michael T.
    Milton, Denai
    Perez, Kristen
    Davies, Michael A.
    Rai, Kunal
    Wargo, Jennifer Ann
    Tawbi, Hussein Abdul-Hassan
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [47] Efficacy and safety of venetoclax plus azacitidine for patients with treatment-naive high-risk myelodysplastic syndromes
    Garcia, Jacqueline S.
    Platzbecker, Uwe
    Odenike, Olatoyosi
    Fleming, Shaun
    Fong, Chun Yew
    Borate, Uma
    Jacoby, Meagan A.
    Nowak, Daniel
    Baer, Maria R.
    Peterlin, Pierre
    Chyla, Brenda
    Wang, Huipei
    Ku, Grace
    Hoffman, David
    Potluri, Jalaja
    Garcia-Manero, Guillermo
    BLOOD, 2025, 145 (11) : 1126 - 1135
  • [48] Correction to: Evaluation of the bioequivalence and food effect on the bioavailability of CC-486 (oral azacitidine) tablets in adult patients with cancer
    Hani M. Babiker
    Mohammed Milhem
    Joseph Aisner
    William Edenfield
    Dale Shepard
    Michael Savona
    Swaminathan Iyer
    Maen Abdelrahim
    C. L. Beach
    Barry Skikne
    Eric Laille
    Kao-Tai Tsai
    Thai Ho
    Cancer Chemotherapy and Pharmacology, 2020, 85 : 1009 - 1010
  • [49] Outcome of Patients with Lower-Risk Myelodysplastic Syndrome (MDS) After Azacitidine (AZA) Treatment Failure.
    Mishra, Asmita
    Lancet, Jeffrey E.
    Al Ali, Najla H.
    Padron, Eric
    Ho, Viet Q.
    Little, Bryan J.
    Pinilla-Ibarz, Javier
    List, Alan F.
    Komrokji, Rami S.
    BLOOD, 2012, 120 (21)
  • [50] Efficacy, safety, and pharmacokinetics of subcutaneous azacitidine in Taiwanese patients with higher-risk myelodysplastic syndromes
    Chou, Wen-Chien
    Yeh, Su-Peng
    Hsiao, Liang-Tsai
    Lin, Sheng-Fung
    Chen, Yeu-Chin
    Chen, Tsai-Yun
    Laille, Eric
    Galettis, Anoula
    Dong, Qian
    Songer, Steve
    Beach, C. L.
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2017, 13 (05) : E430 - E439
12345